Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate
Non-randomised trial
OA: closed
CC0
⤵ 14 in-corpus citations
AI-generated summary
This study investigated alterations in lipoprotein profiles in women with pelvic endometriosis undergoing treatment with medroxyprogesterone acetate.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Ten women with endometriosis were treated with medroxyprogesterone acetate (MPA), 150 mg intramuscularly every second week. After 2 weeks, there was a significant (8%) decrease in the high-density lipoprotein (HDL) concentration. This reduction became more pronounced after 8 and 24 weeks' medication. The HDL reduction was confined to the HDL2 subfraction, which was decreased by 15%, 33%, and 58% after 2, 8, and 24 weeks, respectively; there was no significant change in the HDL3 concentration. During treatment, there was a continuous increase in the mean MPA plasma level and a strong inverse correlation between this level and the mean HDL and HDL2 cholesterol concentrations. It was concluded that MPA affects HDL metabolism in a dose-dependent way and in the same direction as other progestins.
My notes (saved in your browser only)
Condition tags
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (15)
- Cholesterol, high density lipoprotein and danazol via openalex
- Effects of danazol and lynestrenol on serum lipoproteins in endometriosis via openalex
- Profound alterations of the lipoprotein metabolism during danazol treatment in premenopausal women via openalex
- W1975188266 via openalex
- W1984307866 via openalex
- W2016842329 via openalex
- W2067362732 via openalex
- W1973843968 via openalex
- W2082468404 via openalex
- W2142173846 via openalex
- W2166737192 via openalex
- W2167396895 via openalex
- W1622727022 via openalex
- W2338124628 via openalex
- W1533375993 via openalex
Cited by (13)
- Emerging hallmarks of endometriosis metabolism: A promising target for the treatment of endometriosis 2022
- Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile 2007
- The role of progestins in treating the pain of endometriosis 2006
- Subdermal progestin implant (Nestorone) in the treatment of endometriosis: clinical response to various doses 2003
- ACOG practice bulletin. Medical management of endometriosis. Number 11, December 1999 (replaces Technical Bulletin Number 184, September 1993). Clinical management guidelines for obstetrician-gynecologists 2000
- Medical Treatment of Endometriosis-Associated Pain 1999
- Endometriosis: critical assessment of current therapies 1998
- Endometriosis and Pelvic Pain 1998
- Changing concepts of medical treatment of endometriosis 1993
- Medical treatment of mild endometriosis associated with infertility 1991
- Lipid metabolism during treatment of endometriosis with the progestin dienogest 1989
- LH-RH agonist (buserelin): treatment of endometriosis. Clinical, laparoscopic, endocrine and metabolic evaluation 1989
- Lipid metabolic changes during hormonal treatment of endometriosis 1988
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK